Neonatal Outcomes in Maternal Heart Disease: A Multidisciplinary Approach toward Congenital and Acquired Conditions
Main Article Content
Abstract
Background: Neonatal outcomes are directly affected by maternal heart disease, which remains one of the leading causes of preventable pregnancy-related deaths in the United States. Limited data compares maternal and neonatal outcomes among this high-risk population. We describe neonatal outcomes among pregnancies with and without heart disease in a tertiary care center with coordinated multidisciplinary care.
Methods: This was a cohort study of pregnancies affected by maternal cardiac diseases that received multidisciplinary care (maternal-fetal-medicine, obstetrics, cardiology, anesthesiology, genetics) in a single tertiary center between 2012 and 2024. Study groups consisted of pregnancies with maternal acquired heart disease (AHD) (n = 242), maternal congenital heart disease (CHD) (n = 224), and a comparison group of pregnancies without maternal heart disease from November 2020 through April 2021 (n = 183). Neonatal outcomes including birth weight, gestational age, Apgar scores, and NICU admissions, were compared by Pearson Chi-Square, Fisher Exact, and Kruskal-Wallis rank sum tests. A pairwise comparison was conducted for significant differences. A sensitivity analysis was performed by logistic and linear regression to adjust for beta-blocker use during pregnancy. Significance was set at alpha = 0.05.
Results: Maternal heart disease, particularly CHD, was associated with increased adverse neonatal outcomes compared to the comparison cohort. Infants born to people with CHD or AHD had lower birth weights, shorter gestational ages, lower Apgar scores, and higher NICU admission rates compared to those without heart disease (Table 1) (p < 0.01 for all comparisons). The proportion of small for gestational age infants born to people with CHD was significantly higher than those born to people with AHD (p = 0.007). After adjusting for beta-blocker exposure during pregnancy, the odds for small for gestational age in neonates of patients with CHD were 2.29 times higher than in those with AHD (p = 0.006). All other outcomes were similar in the CHD and AHD cohorts.
Conclusion: Maternal heart disease is associated with increased risk of adverse neonatal outcomes, necessitating a multidisciplinary approach in prenatal care. Infants born to individuals with CHD had a higher risk for small for gestational age compared to those with AHD. Further studies are needed to better understand this biological difference.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Collier AY, Molina RL. Maternal mortality in the United States: updates on trends, causes, and solutions. NeoReviews. 2019;20(10):e561-e574. doi:10.1542/neo.20-10-e561
3. California Maternal Quality Care Collaborative. CA-PAMR recent data. Accessed July 1, 2025. https://www.cmqcc.org/research/maternal-mortality-review-ca-pamr/ca-pamr-recent-data
4. MBRRACE-UK. Maternal mortality 2020-2022. National Perinatal Epidemiology Unit. Accessed July 1, 2025. https://www.npeu.ox.ac.uk/mbrrace-uk/data-brief/maternal-mortality-2020-2022#causes-of-maternal-deaths-uk-2020-2022
5. Saucedo M, Deneux-Tharaux C. Maternal mortality in France, 2016–2018: frequency, causes and women’s profile. Gynecol Obstet Fertil Senol. 2024;52(4):185-200. doi:10.1016/j.gofs.2024.02.020
6. Mehta LS, Warnes CA, Bradley E, Burton T, Economy K, Mehran R, Safdar B, Sharma G, Wood M, Valente AM, Volgman AS, & On behalf of the American Heart Association Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and Stroke Council. Cardiovascular Considerations in Caring for Pregnant Patients: A Scientific Statement From the American Heart Association. Circulation, 2020;141(23). https://doi.org/10.1161/CIR.0000000000000772
7. Kovacevic, A., Elsässer, M., Fluhr, H., Müller, A., Starystach, S., Bär, S., & Gorenflo, M. (2021). Counseling for fetal heart disease-current standards and best practice. Translational pediatrics, 10(8), 2225–2234. https://doi.org/10.21037/tp-20-181
8. Easter SR, Valente AM, & Economy KE. Creating a Multidisciplinary Pregnancy Heart Team. Current treatment options in cardiovascular medicine, 2020;22(1), 3. https://doi.org/10.1007/s11936-020-0800-x
9. Gonzalez JM, Harris I, Jimenez Ramirez N, Myers D, Killion M, Thiet MP, Bianco K. Maternal cardiac disease and perinatal outcomes in a single tertiary care center. J Matern Fetal Neonatal Med. 2023;36(2). doi:10.1080/14767058.2023.2223336
10. Mayer F, Bick D, Taylor C. Multidisciplinary care for pregnant women with cardiac disease: a mixed methods evaluation. Int J Nurs Stud. 2018;85:96-105. doi:10.1016/j.ijnurstu.2018.05.010
11. Davis M, Arendt K, Bello N, et al. Team-based care of women with cardiovascular disease from pre-conception through pregnancy and postpartum: JACC Focus Seminar 1/5. J Am Coll Cardiol. 2021;77(14):1763-1777. doi:10.1016/j.jacc.2021.02.033
12. Siu SC, Colman JM, Sorensen S, et al. Adverse neonatal and cardiac outcomes are more common in pregnant women with cardiac disease. Circulation. 2002;105(18):2179-2184. doi:10.1161/01.cir.0000015699.48605.08
13. Sahu AK, Harsha MM, Rathoor S. Cardiovascular diseases in pregnancy: a brief overview. Curr Cardiol Rev. 2022;18(1):e250821195824. doi:10.2174/1573403X17666210825103653
14. Gelson E, Curry R, Gatzoulis MA, Swan L, Lupton M, Steer P, Johnson M. Effect of maternal heart disease on fetal growth. Obstet Gynecol. 2011;117(4):886-891. doi:10.1097/AOG.0b013e31820cab69
15. Cauldwell M, Steer P, Sterrenburg M, et al. Birth weight in pregnancies complicated by maternal heart disease. Heart. 2019;105(4):391-398. doi:10.1136/heartjnl-2018-313551
16. Sørbye IK, Haualand R, Wiull H, Letting AS, Langesæter E, Estensen ME. Maternal beta-blocker dose and risk of small-for-gestational-age in women with heart disease. Acta Obstet Gynecol Scand. 2022;101(7):794-802. doi:10.1111/aogs.14363
17. Kong CW, Tay JA, Chen H, Ersbøll AS. Beta-blockers in pregnancy: impacts on the fetus and neonate. Int J Cardiol. 2024. doi:10.1016/j.ijcard.2024.05.031
18. Sperling MM, Leonard SA, Miller SE, Hurtado J, El-Sayed YY, Herrero T, Faig J, Carter S, Blumenfeld YJ. Fasting compared with fed and oral intake before the 1-hour oral glucose tolerance test: a randomized controlled trial. Obstet Gynecol. 2023;141(1):126-133. doi:10.1097/AOG.0000000000005013
19. R Foundation for Statistical Computing. R: A language and environment for statistical computing. Vienna, Austria. https://www.r-project.org/
20. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340
21. Gonzalez JM, Harris I, Jimenez Ramirez N, et al. Maternal cardiac disease and perinatal outcomes in a single tertiary care center. J Matern Fetal Neonatal Med. 2023;36(2):2223336. doi:10.1080/14767058.2023.2223336
22. Bender A, Heimann K, Tinneberg HR, et al. Neonatal outcomes and length of NICU stay in pregnancies complicated by maternal heart disease. Arch Gynecol Obstet. Published online 2024. doi:10.1055/a-2311-4945
23. Snoep MC, Aliasi M, van der Meeren LE, Jongbloed MRM, DeRuiter MC, Haak MC. Placenta morphology and biomarkers in pregnancies with congenital heart disease: a systematic review. Placenta. 2021;112:189-196. doi:10.1016/j.placenta.2021.07.297
24. Ho DY, Josowitz R, Katcoff H, et al. Mid-gestational fetal placental blood flow is diminished in the fetus with congenital heart disease. Prenat Diagn. 2020;40(11):1432-1438. doi:10.1002/pd.5791
25. Rychik J, Donofrio MT, Falkensammer CB, et al. Fetal cardiovascular physiology in congenital heart disease. Circulation. 2014;129(13):1349-1361. doi:10.1161/CIRCULATIONAHA.113.005701
26. White D. Development of a center of excellence for caring for pregnant women who have heart disease. J Obstet Gynecol Neonatal Nurs. 2019;48(3 Suppl):S21.
27. Canobbio MM, Warnes CA, Aboulhosn J, et al. Management of pregnancy in patients with complex congenital heart disease: a scientific statement from the American Heart Association. Circulation. 2017;135(8):e50-e87. doi:10.1161/CIR.0000000000000458
28. Ramlakhan KP, Roos-Hesselink JW, Basso T, et al; ROPAC Investigators. Perinatal outcomes after in utero exposure to beta-blockers in women with heart disease: data from the ESC EORP registry of pregnancy and cardiac disease (ROPAC). Int J Cardiol. 2024;410:132234. doi:10.1016/j.ijcard.2024.132234
29. Bateman BT, Patorno E, Desai RJ, et al. Late pregnancy β blocker exposure and risks of neonatal hypoglycemia and bradycardia. Pediatrics. 2016;138(3):e20160731. doi:10.1542/peds.2016-0731
30. Nicholls-Dempsey L, Badeghiesh A, Baghlaf H, Dahan MH. How does high socioeconomic status affect maternal and neonatal pregnancy outcomes? A population-based study among American women. Eur J Obstet Gynecol Reprod Biol X. 2023;20:100248. doi:10.1016/j.eurox.2023.100248
31. Armstrong L, Stenson BJ. Use of umbilical cord blood gas analysis in the assessment of the newborn. Arch Dis Child Fetal Neonatal Ed. 2007;92(6):F430-F434. doi:10.1136/adc.2006.099846